Nearing Launch of its MiSeq Instrument, Illumina Says Initial Data is Comparable to HiSeq

According to an Illumina official, the MiSeq will be suited for metagenomics, de novo assembly of small organisms, and especially for the clinical market, as the company plans to apply for FDA 510(k) approval for the instrument.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.